nach oben

Erschienen in:

19.02.2019 | Research Article

Mitotic rate as an important prognostic factor in cutaneous malignant melanoma

verfasst von: A. Piñero-Madrona, G. Ruiz-Merino, P. Cerezuela Fuentes, E. Martínez-Barba, J. N. Rodríguez-López, J. Cabezas-Herrera

Erschienen in: Clinical and Translational Oncology | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Recently, the quantification of mitoses in cutaneous melanoma has been discharged from the main prognostic variables of the TNM classification.

Objective

To investigate the prognostic value of the presence of mitoses in primary cutaneous melanoma and to establish the number of mitoses per mm² that may have prognostic significance.

Methods

A retrospective observational study was performed on 141 patients treated for cutaneous melanoma, who were assessed by the same pathologist, and who had a minimum follow-up of 2 years. Clinical, epidemiological, histopathological and follow-up variables were gathered and compared with the number of mitoses to distinguish the significance of differences by means of univariate, multivariate, and survival analyses.

Results

The cut-off level related to a better sensitivity and specificity was 1.50 mitoses per mm². The presence of two or more mitoses/mm² showed a better relationship with prognostic variables and both the overall and disease-free survival than the presence of 1 or more mitoses/mm². This happens especially in melanomas thicker than 0.8 mm and it could affect the staging in cases with Breslow between 1 and 2 mm.

Conclusions

A mitotic rate of two or more mitoses per mm² in cutaneous melanoma should be considered as a more accurate prognostic factor than one or more mitoses per mm², particularly in tumors equal or greater than 0.8 mm in thickness.

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Manual. 7th edition. New York: Springer; 2010.

Caldarella A, Fancelli L, Manneschi G, et al. How staging of thin melanoma is changed after the introduction of TNM 7th edition: a population based study. J Cancer Res Clin Oncol. 2016;142:73–6.CrossRefPubMed

de Waal AC, van Harten-Gerritsen AS, Aben KK, et al. Impact of mitotic activity on the pathological substaging of pT1 cutaneous melanoma. Br J Dermatol. 2014;170:874–7.CrossRefPubMed

Ponti G, Pollio A, Cesinaro AM, et al. Value and prognostic significance of mitotic rate in a retrospective series of pT1 cutaneous malignant melanoma patients. Cancer Epidemiol. 2012;36:303–5.CrossRefPubMed

Lardon AR, Rothschild B, Walls AC, et al. Impact of the 2009 AJCC staging guidelines for melanoma on the number of mitotic figures reported by dermatopathologists al one institution. J Cutan Pathol. 2015;42:536–41.CrossRef

Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29:2199–205.CrossRefPubMedPubMedCentral

Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma of the skin, chapter 4. In: Amin MB, Edge SB, Greene FL, et al., editors. AJCC Cancer Staging Manual. 8th edition. Cham: Springer International Publishing AG; 2017. p. 563–585.

Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004;11:426–33.CrossRefPubMed

Maurichi A, Miceli R, Camerini T, et al. Prediction of survival in patients with thin melanoma: results from a multiinstitution study. J Clin Oncol. 2014;32:2479–85.CrossRefPubMed

10.

Murali R, Moncrieff MD, Hong J, Cooper CL, Shingde MV, Samuel DG, Thompson JF, Scolyer RA. The prognostic value of tumor mitotic rate and other clinicopathologic factors in patients with locoregional recurrences of melanoma. Ann Surg Oncol. 2010;17:2922–99.CrossRef

11.

Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, Guery D. Biologic and prognostic significance of dermal ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23:8048–56.CrossRefPubMed

12.

Barnhill RL, Katzen J, Spatz A, Fine J, Berwick M. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol. 2005;32:268–73.CrossRefPubMed

13.

Elder DE, Gimotty PA, Guerry D. Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features. Dermatol Ther. 2005;18:369–85.CrossRefPubMed

14.

Scolyer RA, Thompson JF. Mitotic rate in melanoma should be recorded as the number of mitosis per mm2 (not per high power field): surgeons tell your pathologists! Am J Surg. 2013;206:142–3.CrossRefPubMed

15.

Scolyer RA, Shaw HM, Thompson JF, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;27:1571–6.CrossRefPubMed

16.

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, et al. Multivariate analysis of prognostic factors amon 2,313 patients with stage III melanoma: comparison of nodal micrometastases and macrometastases. J Clin Oncol. 2010;28:2452–9.CrossRefPubMedPubMedCentral

17.

National Comprehensive Cancer Network: NCCN Guidelines^® Version 2.2016: Melanoma NCCN Evidence Blocks™. p. ME-3.

18.

Namikawa K, Aung PP, Gershenwald JE, Milton DR, Prieto VG. Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study al a comprehensive cancer center. Cancer Med. 2018;7:583–93.CrossRefPubMedPubMedCentral

19.

Evans JL, Vidri RJ, MacGillivray DC, Fitzgerald TL. Tumor mitotic rate is an independent predictor of survival for nonmetastatic melanoma. Surgery. 2018;164:589–93.CrossRefPubMed

20.

Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12:449–58.CrossRefPubMed

21.

Ottmann K, Tronnier M, Mitteldorf C. Detection of mitotic figures in thin melanomas: immunohistochemistry does not replace the careful search for mitotic figures in hematoxylin–eosin stain. J Am Acad Dermatol. 2015;73:637–44.CrossRefPubMed

22.

Lou S, Lobo AZC, Tanabe KK, Muzikansky A, Durazzo T, Sober A, Tsao H, Osimi B, Lawrence DP, Duncan LM. Clinical significance of microscopic melanoma metastases in the nonhottest sentinel lymph nodes. JAMA Surg. 2015;150:465–72.CrossRef

23.

Han D, Zager JS, Shyr Y, et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol. 2013;31:4387–93.CrossRefPubMed

24.

Speijers MJ, Bastiaannet E, Sloot S et al. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? A single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients. Ann Surg Oncol. 2015;22:2978–87.CrossRefPubMed

25.

Wat H, Senthiselvan A, Salopek TG. A retrospective multicenter analysis of the predictive value of mitotic rate for sentinel lymph node positivity in thin melanoma. J Am Acad Dermatol. 2016;74:94–101.CrossRefPubMed

26.

Wheless L, Isom CA, Hooks MA, Kauffmann RM. Mitotic rate is associated with positive lymph nodes in thin melanoma. J Am Acad Dermatol. 2017. https://doi.org/10.1016/j.jaad.2017.11.041.CrossRefPubMedPubMedCentral

27.

Baker JJ, Meyers MO, Deal AM, et al. Prognostic significance of tumor mitotic rate in T2 melanoma staged with sentinel lymphadenectomy. J Surg Oncol. 2015;111:711–5.CrossRefPubMed

28.

Kibrité A, Milot H, Douville P, et al. Predictive factors for sentinel lymph nodes and non-sentinel lymph nodes metastatic involvement: a database study of 1041 melanoma patients. Am J Surg. 2016;211:89–94.CrossRefPubMed

29.

Kirkland EB, Zitelli JA. Mitotic rate for thin melanomas: should a single mitotic figure warrant a sentinel lymph node biopsy? Dermatol Surg. 2014;40:937–45.CrossRefPubMed

30.

Betti R, Santambrogio R, Cerri A, et al. Observational study on the mitotic rate and other prognostic factors in cutaneous primary melanoma arising from naevi and from melanoma de novo. J Eur Acad Dermatol Venereol. 2014;28:1736–41.CrossRef

31.

Lorimer PD, Benham EC, Walsh K, et al. Reporting of mitotic rate in cutaneous melanoma: a study usnig the national cancer data base. J Surg Oncol. 2017;115:281–6.CrossRefPubMed

32.

Roncati L, Piscioli F, Pusiol T. The importance of mitotic rate reporting in primary cutaneous melanoma. J Surg Oncol. 2017;116:958–9.CrossRefPubMed

33.

Tejera-Vaquerizo A, Pérez-Cabello G, Martínez-Leborans L, et al. Is mitotic rate still useful in the management with thin melanoma? JEADV. 2017;31:2025–9.PubMed

Titel: Mitotic rate as an important prognostic factor in cutaneous malignant melanoma
verfasst von: A. Piñero-Madrona
G. Ruiz-Merino
P. Cerezuela Fuentes
E. Martínez-Barba
J. N. Rodríguez-López
J. Cabezas-Herrera
Publikationsdatum: 19.02.2019
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 10/2019
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-019-02064-4

Springer Medizin

Mitotic rate as an important prognostic factor in cutaneous malignant melanoma